1. Home
  2. KPLT vs GRDX Comparison

KPLT vs GRDX Comparison

Compare KPLT & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$6.24

Market Cap

34.3M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$3.00

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
GRDX
Founded
2012
N/A
Country
United States
United Kingdom
Employees
87
2
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.3M
28.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KPLT
GRDX
Price
$6.24
$3.00
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
6.1K
56.6K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.62
N/A
Revenue Next Year
$15.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$1.87
52 Week High
$24.15
$6.93

Technical Indicators

Market Signals
Indicator
KPLT
GRDX
Relative Strength Index (RSI) 38.00 39.54
Support Level $5.89 $2.01
Resistance Level $6.79 $3.65
Average True Range (ATR) 0.49 0.38
MACD -0.11 -0.01
Stochastic Oscillator 17.37 26.35

Price Performance

Historical Comparison
KPLT
GRDX

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: